MRKRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Marker Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.20+0.16 (+15.38%)
Close on Oct 19, 2026
- Market cap
- $23.18M
- P/E (TTM)
- –
- Dividend yield
- –
Marker Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Marker Therapeutics | Industry median |
|---|---|---|
| Market Cap | $20.01M | $164.85M |
| Enterprise Value | $8.68M | $87.06M |
| PB Ratio | 1.64 | 2.03 |
| P/TBV Ratio | 1.64 | 2.31 |
Income (trailing twelve months)
| Measure | Marker Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$10.71M | -$21.44M |
| Net Income | -$8.71M | -$22.46M |
| EBITDA | -$10.71M | -$16.91M |
| EPS (Diluted) | -$0.46 | -$0.83 |
Returns
| Measure | Marker Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -76.9% | -53.1% |
| Return on Assets (ROA) | -59.3% | -41.0% |
| Return on Capital Employed (ROCE) | -88.1% | -37.8% |
Growth
| Measure | Marker Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | 0.31% | 2.25% |
| Revenue Growth (5Y CAGR) | 48.0% | 6.42% |
Balance sheet
| Measure | Marker Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $11.33M | $62.42M |
| Net Cash (Debt) | $11.33M | $15.68M |
| Net Cash Per Share | $0.68 | $0.66 |
| Equity (Book Value) | $12.17M | $48.79M |
| Book Value Per Share | $0.73 | $1.36 |
| Tangible Book Value | $12.17M | $23.06M |
| Working Capital | $12.17M | $75.77M |
Financial position
| Measure | Marker Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 6.03 | 3.30 |
| Quick Ratio | 4.68 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Marker Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$9.76M | -$12.35M |
Efficiency
| Measure | Marker Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.74M | -$703.34K |
| Employee Count | 5 | 74 |
Dividends and yields
| Measure | Marker Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -43.5% | -22.7% |
Shares
| Measure | Marker Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 16,673,100 | 58,179,650 |
| Shares Change (YoY) | 73.2% | 11.1% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 11,350,000 | 49,173,100 |
| Shares Held by Insiders | 31.9% | 11.6% |
| Shares Held by Institutions | 23.8% | 59.4% |
Scores
| Measure | Marker Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -41.02 | -0.24 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Marker Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.